Palantir Looks Like a Solid Buy, but Not Right Now
Palantir Looks Like a Solid Buy, but Not Right Now
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股市新闻、股票建议和交易提示
After reporting mixed earnings, shares of Palantir (NYSE:PLTR) are below their direct listing price. And with the company suggesting that next quarter's revenue may come in below analysts' estimates, the immediate question may be how low can the stock go? Until investors can figure that out, PLTR stock is not a buy.
在公布收益喜忧参半后，的股票 帕兰蒂尔 （纽约证券交易所：PLTR) 低于他们的直接上市价格。该公司暗示下一季度的收入可能低于分析师的预期，因此眼前的问题可能是该股能跌到多低？在投资者弄清楚这一点之前，PLTR股票不是买入。
However, in strictly technical terms, the sell-off is starting to look overdone. Plus, the lower the stock goes, the more it starts to look appealing from a fundamental perspective. And that means that PLTR stock looks like it will be a solid buy at some point. But with investor sentiment at all-time bearish levels, that day is not today.
但是，从严格的技术角度来看，抛售开始显得过分了。另外，从基本面角度来看，该股走低就越有吸引力。这意味着PLTR股票在某个时候看起来会是一个稳健的买盘。但是，由于投资者情绪处于历史看跌水平，那一天不是今天。
The more interesting question for me is what more does Palantir have to do to please investors? Upon going public, a key concern of investors was the company's reliance on its government contracts. But in its most recent earnings report, Palantir showed a 54% year-over-year (YOY) increase in sales on the commercial side of its business. Overall revenue was up 31% YOY, which was slightly ahead of analysts' expectations.
对我来说，更有趣的问题是，为了取悦投资者，Palantir还需要做些什么？上市后，投资者最关心的问题是该公司对政府合同的依赖。但在最新的财报中，Palantir显示，其商业方面的销售额同比增长了54％。总收入同比增长31％，略高于分析师的预期。
Ironically, it's slower growth in the company's government-related revenue that is causing angst for investors post earnings. Palantir reported that vertical only saw a 16% YOY revenue increase. Plus the company is forecasting slower overall revenue growth for the second quarter.
具有讽刺意味的是，该公司与政府相关的收入增长放缓引起了财报公布后的投资者的焦虑。Palantir报告称，该垂直行业的收入仅同比增长16％。此外，该公司预计第二季度的整体收入增长将放缓。
- 7 Defensive Dividend Healthcare Stocks to Buy Now
- 现在要买入的7只防御性股息医疗保健股
However, it's unclear whether investors are factoring in two recently announced contracts. First, the company announced a 10 million-pound ($12.5 million) contract with the U.K. Ministry of Defence. And the company also inked a 5-year, $90-million blanket purchase agreement with the Department of Health and Human Services (HHS).
但是，目前尚不清楚投资者是否考虑了最近宣布的两份合约。首先，该公司宣布了 一千万英镑（合1,250万美元）的合同 与英国国防部合作。而且该公司还签署了一份 为期 5 年、价值 9000 万美元的一揽子购买协议 与卫生与公共服务部（HHS）合作。
It's fair to note that Palantir missed on earnings. And this does nothing to satisfy investors who are concerned that Palantir may find it difficult to generate meaningful earnings. The root of this concern is that the data analytics company faces too much competition to capture significantly higher market share than it already has.
可以公平地指出，Palantir错过了收益。这并不能满足那些担心Palantir可能难以产生有意义的收益的投资者。这种担忧的根源在于，这家数据分析公司面临着过于激烈的竞争，无法获得比现在高得多的市场份额。
Still, Palantir has a consensus price target of $14.31, an 85% gain from the stock's current price. It's also over 40% lower than the consensus price target from a year ago. That's not very comforting for investors who bought PLTR stock at its 2021 highs, but it presents an intriguing opportunity for risk-tolerant investors.
尽管如此，Palantir的共识目标股价仍为14.31美元，比该股的当前价格上涨了85％。它也比去年同期的共识目标价格低了40％以上。对于在2021年高点购买PLTR股票的投资者来说，这并不是很令人欣慰，但它为风险承受能力的投资者提供了一个有趣的机会。
On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在发布之日，克里斯·马尔科赫（Chris Markoch）没有（直接或间接）持有本文提到的证券的任何头寸。本文中表达的观点是作者的观点，但以InvestorPlace.com为准 出版指南。
The post Palantir Looks Like a Solid Buy, but Not Right Now appeared first on InvestorPlace.
《Palantir 看起来像一个稳健的买入，但现在不是》一文首次出现在 InvestorPlace 上。
